Moderna, Inc.
MRNAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Moderna, Inc. focuses on Biotechnology services and products. Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. At a $58.11B market cap, Moderna, Inc. ranks as a large-cap company within healthcare. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines.
Market Cap
$58.11B
Beta
1.11
P/E (TTM)
—
P/E (Fwd)
-31.69
EPS (TTM)
$-7.98
EPS (Fwd)
$-4.59
ROE
-39.0%
ROA
-13.3%
Cash
$5.14B
Total Debt
$1.29B
Free CF
$299.2M
52W Change
494.8%
Annual Financials
Cash vs Debt
Where MRNA stands vs its 150-day and 200-day moving averages
As of the August 27, 2026 close, MRNA finished 160.73% above its 150-day moving average ($57.40) and 195.71% above its 200-day moving average ($50.61). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MRNA overbought or oversold?
At the August 27, 2026 close, MRNA's RSI(14) was 72.5, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $5.14B in cash and $1.29B in debt, MRNA maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow comes in at $299.2M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of -39.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $18.88B (2022) to $1.92B (2025), a 90% decline worth watching.
With cash comfortably exceeding debt, MRNA has financial flexibility that may help navigate uncertain periods. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Moderna, Inc.'s trajectory.